Thrombotic microangiopathy is prevented in a case series of pig-to-human kidney xenotransplantation

In this episode, Jayme Locke and Maggie Jones-Carr explain the histologic outcomes of a series of brain-dead human recipients of a porcine kidney xenotransplant using exclusively FDA-approved medications, with and without anti-C5 monoclonal antibody.

Published March 1, 2024, by Megan Jenkins

Related articles

C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation
Maggie E. Jones-Carr, … , Paige M. Porrett, Jayme E. Locke
Maggie E. Jones-Carr, … , Paige M. Porrett, Jayme E. Locke
Published January 25, 2024
Citation Information: J Clin Invest. 2024;134(5):e175996. https://doi.org/10.1172/JCI175996.
View: Text | PDF
Research Letter Nephrology Transplantation

C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation

Abstract

Authors

Maggie E. Jones-Carr, Huma Fatima, Vineeta Kumar, Douglas J. Anderson, Julie Houp, Jackson C. Perry, Gavin A. Baker, Leigh McManus, Andrew J. Shunk, Paige M. Porrett, Jayme E. Locke

×
Advertisement